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Huntington’s disease is characterized by a complex and heterogeneous pathogenic profile. Studies have 
shown that disturbance in lipid homeostasis may represent a critical determinant in the progression 
of several neurodegenerative disorders. The recognition of perturbed lipid metabolism is only recently 
becoming evident in HD. In order to provide more insight into the nature of such a perturbation and into 
the effect its modulation may have in HD pathology, we investigated the metabolism of Sphingosine-
1-phosphate (S1P), one of the most important bioactive lipids, in both animal models and patient 
samples. Here, we demonstrated that S1P metabolism is significantly disrupted in HD even at early 
stage of the disease and importantly, we revealed that such a dysfunction represents a common 
denominator among multiple disease models ranging from cells to humans through mouse models. 
Interestingly, the in vitro anti-apoptotic and the pro-survival actions seen after modulation of S1P-
metabolizing enzymes allows this axis to emerge as a new druggable target and unfolds its promising 
therapeutic potential for the development of more effective and targeted interventions against this 
incurable condition.
Huntington’s disease (HD), the most common dominantly inherited neurodegenerative disorder affecting an 
estimated 3 to 7 per 100,000 people, is associated with progressive motor, cognitive and behavioral disturbances1. 
The disease-causing mutation is an expansion of CAG trinucleotide repeats (>36 repeats) within the HTT gene 
encoding a polyglutamine (polyQ) stretch in the N-terminal region of Huntingtin (Htt), a ubiquitous protein 
whose function is still unclear2. Expansion of the polyQ stretch endows mutant Htt (mHtt) with toxic properties 
and results in a range of cellular abnormalities3 including aberrant metabolism of brain lipids4–9.
Sphingolipids represent the major lipid component of biological membranes and regulate a number of 
important cellular functions10. Ceramide (Cer), sphingosine (Sph) and its phosphorylated form Sphingosine-
1-phosphate (S1P) are key intermediates in the sphingolipid metabolism10, 11 (Fig. 1) and thus tightly regulated. 
S1P is found both within the intracellular and extracellular compartments12–14 and outside the cell, it acts as a high 
affinity agonist at five known G protein-coupled receptors, which are highly expressed in the brain12, 15.
S1P metabolism is a complex process and normally implicates a number of different enzymes (see Fig. 1). 
Sphingosine kinase 1 and 2 (SPHK1/2) catalyze the phosphorylation of Sph to generate S1P16. Under normal 
conditions, SPHK1 activity is associated with cell survival17, 18, while SPHK2 has a more complex effect – coordi-
nating a number of intracellular pathways such that it leads to loss of cell growth and apoptosis when altered18–22. 
On the other hand, the degradative enzyme Sphingosine-1-phosphate Lyase1 (SGPL1) plays a key role in main-
taining the right balance between S1P levels and other sphingolipid intermediates all of which affect cell growth, 
proliferation and cell death23. Indeed, uncontrolled up-regulation of SGPL1 results in a reduced availability of the 
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bioactive lipid and a concomitant release of hexadecenal whose accumulation is cytotoxic in vitro24. Up-regulation 
of SGPL1 along with reduced levels of SPHK1 and subsequent decreased content of S1P has been found to be also 
associated with neurodegeneration in Alzheimer’s disease (AD)25–27.
Abnormal levels of both SPHK1 and 2 have been, indeed, described in experimental models of Parkinson’s 
disease (PD)28. Expression of SPHK1 has been reported to be significantly decremented also in a mouse model 
of HD29. Whether an imbalance in the S1P-metabolizing enzymes may further contribute to the worsening of 
the disease is still unclear, however, recent evidence demonstrates that either overexpression of SPHK1 or inhi-
bition of SPHK2 is beneficial in an in vitro model of the disease30, 31. Further support for the importance of this 
pathway to HD comes from the evidence that there is a reduced content of S1P in HD mouse striatal-derived cell 
lines (STHdh)32. Along this line, previous findings from our group and others have shown that administration 
of sphingolipids or sphingomimetic molecules mitigates the toxic effect of mHtt both in in vitro and in vivo33–35, 
all of which adds further weight to the hypothesis that aberrant sphingolipid metabolism is a key feature of the 
disease.
In summary, there is clear evidence for alteration of the sphingolipid metabolism in AD and PD36–39 but with 
only limited evidence to suggest this may also be the case in HD.
We therefore sought to further investigate whether deregulated metabolism of these lipids is a critical abnor-
mality in HD using both animal models and patient samples. We report not only that such abnormalities are 
found in all cases and importantly early in the disease, but that pharmacological interventions aimed at modu-
lating the activity of the sphingolipid metabolizing-enzymes may likely have disease-modifying effects in vivo.
Material and Methods
Human brain tissues. The “Cambridge Brain Bank” (Cambridge, UK) provided anonymous post-mortem 
brain samples (fresh frozen and paraffin-embedded tissues) from HD cases and healthy age-matched controls. All 
studies on human post-mortem brain tissues were approved by Neuromed Ethic Commitee (IRCCS Neuromed, 
RI 002012). The pathological severity of HD was scored according to the Vonsattel grading system40. Subjects’ 
clinical and genetic data are reported in Table 1. Total lysate preparation Tissues were homogenized in lysis buffer 
containing 20 mMTris, pH 7.4, 1% Nonidet P-40, 1 mM EDTA, 20 mMNaF, 2 mM Na3V04, and protease inhibitor 
mixture (Santa Cruz, Cat N. sc-29131) and sonicated with 2 × 10 s pulses. Immunohistochemistry. Deparaffinized 
striatal and cortical tissue sections were soaked in 3% hydrogen peroxide to block endogenous peroxidase activity, 
Figure 1. Simplified sphingolipid metabolic pathway. Ceramide (Cer) is generated through the degradation 
of either Sphingomyelin (SM) or Glycosphingolipids(GLS) by Sphingomyelin Phosphodiesterase (SMPD) and 
GlucosylCeramidase (GBA) respectively. Cer is subsequently metabolized by Ceramidase (CDse) to generate 
Sphingosine (Sph), which in turn produces Sphingosine-1-Phosphate (S1P) through phosphorylation by 
Sphingosine Kinase-1 and Sphingosine Kinase-2 (SPHK1/2). All these reactions are reversible. S1P can be 
catabolized into hexadecenal and  phospho-ethanolamine by S1P Lyase (SGPL1).
Cases Age Gender
Vonsattel’ 
neuropathology grade
CAGs (normal/
expanded)
1 Healthy Control 67 M CTRL N/A
2 Healthy Control 75 M CTRL N/A
3 Healthy Control 72 M CTRL N/A
4 Manifest HD 66 M III 17/45
5 Manifest HD 73 M III 21/45
6 Manifest HD 68 M IV 19/45
Table 1. Clinical and genetic data of human post-mortem brain tissues.
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incubated for 15 min in boiling citric acid buffer (10 mM, pH 6.0) and allowed to cool down at room temperature 
for 20 minutes. Slides were then washed in TBS and incubated with goat serum for 1 hour at room temperature. 
Sections were then incubated with anti-SGPL1 antibody (1:50) (Santa Cruz, Cat. N. sc-67368) overnight at 4 °C. 
Slides were washed in TBS and then incubated with biotinylated anti-rabbit IgG secondary antibody (Vectors 
Laboratories, Cat. N. BA-1000) for 1 hour at room temperature followed by horseradish peroxidase streptavidin 
(Vectors Laboratories, Cat. N. SA-5004). 3,3′-Diaminobenzidine tetrachloride (DAB) (Sigma Aldrich, Cat. N. 
D4293-50SET) was used for visualization. Control staining was performed without any primary antibody.
Animal models. Mouse colonies were maintained in the animal facility at IRCCS Neuromed. All animal 
studies were performed in accordance with approved protocols by the IRCCS Neuromed Animal Care Review 
Board and by “Istituto Superiore di Sanità” (permit number: 1163/2015- PR) and were conducted according to 
EU Directive 2010/63/EU for animal experiments. All the analyses were performed on manifest early manifest (6 
week old) and on manifest (11 week old) R6/2 and manifest (9 month old) YAC128 HD mice and age-matched 
wild-type (WT) littermates. R6/2 mouse model, overexpressing the exon 1 of the human HD gene (HTT) with 
more than 150 CAG-repeat-expansion41, 42, is one of the best-characterized and the most widely used animal 
model which recapitulates many of the features of HD human pathology and frequently used in preclinical stud-
ies. Motor symptoms usually start at 6 weeks of age and progressively worsen over the weeks41, 42. YAC128 mice 
represent another best-characterized animal model of HD, expressing the entire human HD gene (including 
promoter region) with 128 CAG repeats. Even YAC128 mice display an array of motor and neuropathological 
changes that largely recapitulate the human pathology43. Hyperkinesia begins at 3 months of age with progressive 
motor impairment appearing at 6 months of age.
Total lysate preparation. Mice were sacrificed by cervical dislocation and the entire brain regions (striatum 
and cortex) were dissected out, snap frozen in liquid N2 and pulverized in a mortar with a pestle and the lysate 
obtained as reported above.
Mass Spectrometry. Snap frozen brain tissues were transferred into glass tubes and stored at −80 °C until 
lipid extraction. Lipids were extracted using a modified Bligh and Dyer method. Briefly, brain tissues were 
homogenized in 2 mL CHCl3/MeOH (1:2, v/v) with 0.1% TFA containing internal standards. Then 600 µL of 
both chloroform and water were added with intermittent mixing for 30 sec. The samples were then centrifuged 
for 10 min at 3000 rpm at 4 °C. The organic extracts were divided into two equal parts. One part was evaporated 
under nitrogen stream and reconstituted in 100 µL MeOH/CHCl3 (9:1, v/v) for LCMS analysis of Sphingomyelins, 
Sphingolipid bases and their phosphate metabolites. The other part was fractionated by Silica Gel G (60-Å 230–
400 Mesh ASTM; Sigma-Aldrich, Milan, Italy) column chromatography. Ceramides were eluted with 2 ml of 
CHCl3/MeOH (9:1, v/v), then hexosylceramides were eluted with 1 ml of CHCl3/MeOH (8:2, v/v). Both the frac-
tions were pooled together and evaporated under nitrogen stream and dried pellets were reconstituted in 100 µl 
of MeOH/CHCl3 (9:1, v/v) and transferred to glass vials for LC/MS analyses. LC-MS/MS analyses of the samples 
were carried out on the Acquity UPLC system coupled with a Xevo TQ-MS triple-quadrupole mass spectrometer 
as previously described44.
Analysis of ceramide by immunohistochemistry. For analysis of ceramide, mice were decapitated 
and the entire brain removed and frozen in cool isopentane (−80 °C). Each brain was cut serially with a Jung 
CM1900 Cryostat (Leica Instruments, Germany) in 20 μm thick sections. Brain sections were incubated with 
anti-Ceramide (MID 15B4) (1:200) (Enzo, Cat. N. ALX-804-196; lot number: 06061610)45 over-night at 4 °C and 
then with biotinylated anti-mouse IgG secondary antibody (Vectors Laboratories, Cat. N. BA-2000) for 1 hour 
at room temperature followed by horseradish peroxidase streptavidin (Vectors Laboratories, Cat. N. SA-5004). 
3,3′-Diaminobenzidine tetrachloride (DAB) (Sigma Aldrich, Cat. N. D4293-50SET) was used for detection.
Analysis of ceramide by Dot Blotting. After tissue lysis protein quantitation was first assessed by 
Bradford method. Next, to assure that equal amount of homogenate was analyzed, each sample tissue lysate was 
serially diluted and protein concentration was re-assessed by NanoDrop Spectrophotometer9. Fifty nanograms of 
total protein lysates, from HD and control mice were then spotted in quadruplicates on nitrocellulose membrane 
and, dot-blotting analysis was performed as previously reported9. Ceramides was detected with anti-ceramide 
(1:200) (Enzo, Cat. N. ALX-804-196; lot number: 06061610). A goat anti-mouse HRP-conjugated secondary 
antibody (1:5000) (Santa Cruz, Cat. N. sc-2005; lot number: B0813) was used. Ceramide spots were detected by 
ECL Prime (GE Healthcare) and quantitated with Quantity One (Bio-Rad Laboratories).
Chemicals. (2R, 3S, 4E)-N-methyl-5-(4′-pentylphenyl)-2-aminopent-4-ene-1,3-diol (SK1-I) (Enzo, Cat. N. 
BML-EI411); 2-acetyl-4-(tetrahydroxybutyl)-imidazole (THI) (Cayman, Cat. N. 13222), K145 (Sigma-Aldrich, 
Cat. N. SML1003-5MG), EMD567731 (Cayman, Cat. N. 567731), N,N-Dimethylsphingosine (DMS) (Enzo, Cat. 
N. BML-SL105) and K6PC-5 (NeoPharm, Korea) were dissolved according to the manufacturer’s instruction.
Cell models. Conditionally immortalized mouse striatal knock-in cells expressing endogenous levels of 
wild-type (STHdh7/7) or mHtt (STHdh111/111) were purchased from the Coriell Cell Repositories (Coriell Institute 
for Medical Research, Camden, NJ, USA) and maintained as previously described4. Lysate preparation. Cells were 
lysed in lysis buffer as reported above.
Human iPSC-derived neurons. Neurons were differentiated from previously published representative HD 
hiPSC lines, HD58-3 (58 CAG-repeat expansion), that have been validated to be pluripotent and exhibit cellu-
lar features consistent with HD46. Cortical glutamatergic differentiation was done using a 11day dual SMAD 
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neural induction protocol, as previously described47, 48, except that LDN (4 µM) (Stemgent Cat. N. 04-0074) and 
SB431542 (10 µM) (Stemgent Cat. N.04-0010) was added to the medium throughout the 11 days. Neural induc-
tion was followed by terminal differentiation and maturation in neural differentiation medium consisting of a 
1:1 mixture of N-2 medium (DMEM/F-12 GlutaMAX, N-2 supplement (1x), 100 µm nonessential amino acids, 
100 μM 2-mercaptoethanol, 2000 U/ml penicillin and 2000 µg/ml streptomycin) and B-27-containing neuroba-
sal medium (Neurobasal medium, B-27 supplement (1x), 2 mM Glutamax)49, 50. We have previously confirmed 
expression (protein and/or mRNA) of cortical glutamatergic markers (e.g. vGlut1, glutamate, Sox1, Pax6, FoxG1, 
synapsin, homer along appropriate) using this protocol (data not shown). By day 33 in culture, neuronal pro-
cesses positive for ß3-Tubulin and MAP2 were observed (Supplementary Fig. 1). HD58-3 hiPSC-derived cor-
tical neurons were further differentiated to day 63. On day 63 of differentiation, the neurons were treated with 
accutase (Innovative Cell Technologies Cat. N. AT-104) and re-plated at a density of 1 million cells per 10 cm2 in 
neural differentiation medium containing 10 µM Rock-inhibitor. In K6PC-5 experiments, HD58-3 hiPSCs were 
re-plated from independent wells to provide three experimental replicates. On day 64, the media was changed to 
remove the ROCK inhibitor and the cortical neurons exposed on day 65 to 50 µM K6PC-5 for 30 minutes. Lysate 
preparation. Neuronal cultures were washed once with ice cold PBS and then lysed in 100 µl of RIPA buffer con-
taining protease (Sigma- Aldrich Cat. N. P8340) and phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich Cat. 
N. P5726, Cat. N. P0044), and the lysates centrifuged at 4 °C for 20 min at 20,000 g. The protein concentration of 
the resulting supernatant was quantified using the Pierce BCA Protein Assay (Thermo Scientific). Twenty-five 
micrograms of neuronal proteins were loaded for each sample on a 4–20% pre-cast SDS-PAGE gel (BioRad) and 
run for 3 hours at 90 V. Proteins were then transferred onto nitrocellulose membranes using iBlot Gel Transfer 
Device (Life Technologies) and the gel was stained with Coomassie (BioRad) for 1 hour. The nitrocellulose mem-
brane was blocked in Odyssey Blocking Buffer for 1 hour, and then incubated with anti phospho-AKT and AKT 
Figure 2. Expression of S1P metabolizing enzymes is abnormal in post-mortem brain tissues from HD patients. 
Cropped immunoblottings and densitometric analysis (A) along with representative immunohistochemical 
micrographs (B) of SGPL1 expression in the striatum from post-mortem human brains of manifest HD patients 
and age- and gender-matched healthy controls (see Table 1). Cropped immunoblottings and densitometric 
analysis of SPHK1(C) and SPHK2 isoform expression (D) in the striatum from post-mortem human brains 
of the same subjects. Cropped immunoblottings and densitometric analysis (E) along with representative 
immunohistochemical micrographs (F) of SGPL1 in the cortex from human post-mortem brains of manifest 
HD patients and age- and gender-matched healthy controls. Cropped immunoblottings and densitometric 
analysis of SPHK1(G) and SPHK2 isoform expression (H) in the cortex from post-mortem human brains of the 
same subjects. Scale bar in each micrograph represents 100 µm. In each immunoblotting, all samples were run 
on the same gel. Non-adjacent samples were separated by a black line. Values are mean ± SD. N = 2–3 for each 
group of patients. *p < 0.05 (Unpaired t-test).
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and anti phospho-ERK and ERK antibodies as reported below. Protein bands were detected by ECL Prime (GE 
Healthcare) and quantitated with Quantity One Software (Bio-Rad Laboratories).
Immunoblottings. For SGPL1, SPHK1, SPHK2, twenty-five micrograms of total protein lysate were immu-
noblotted with the following antibodies: anti-SGPL1 (1:1000) (Santa Cruz, Cat. N. sc-67368), anti-SPHK1 
(1:1000) (Abcam, Cat. N. ab71700; lot numbers: GR17790-4 and GR17790-24) and anti-SPHK2 (1:1000) (Abcam, 
Cat. N. ab37977; lot numbers: GR31063-12 and GR31063-39). For phospho-AKT, AKT, phospho-ERK and ERK, 
total lysate was immunoblotted with the following antibodies: anti-phospho-AKT (1:1000) (Cell Signaling, Cat. 
N. 9271), anti-AKT (1:1000) (Cell Signaling Cat. N. 2920), anti-phospho-ERK (1:1000) (Cell Signaling Cat. N. 
9101), anti-ERK (1:1000) (Cell Signaling Cat. N. 9102), and anti-ERK (1:1000) (Cell Signaling Cat. N. 4696). For 
protein normalization, anti-Actin (1:5000) (Sigma Aldrich, Cat. N. A5441) or anti-Cyclophilin (1:3000) (Abcam, 
Cat. N. ab16045) was used. Protein bands were detected by ECL Prime (GE Healthcare) and quantitated with 
Quantity One Software (Bio-Rad Laboratories).
RNA extraction and analysis of gene expression by real-time PCR. Total RNA was extracted 
using RNeasy kit (Qiagen) according to the manufacturer’s instructions. One microgram of total RNA was 
reverse-transcribed using Superscript II reverse transcriptase (Invitrogen) and oligo-dT primer, and the resulting 
cDNAs were amplified using Power SYBR Green PCR Master Mix (Applied Biosystems) following the manufac-
turers’ instructions. Quantitative PCR analysis will be performed on a StepOne instrument (Applied Biosystems) 
using specific the following primers:
mouse SGPL1 Fw: 5′-cattcgacaaagcagctcat-3′;
mouse SGPL1 Rev: 5′-ctcttcattgcctgcacatc-3′;
mouse SPHK1 Fw: 5′-tgtgaaccactatgctgggta-3′;
mouse SPHK1 Rev: 5′-cagcccagaagcagtgtg-3′;
mouse SPHK2 Fw: 5′-agacgggctgctttacga-3′;
mouse SPHK2 Rev: 5′-caggggaggacaccaatg-3′;
mouse Cyclophilin Fw: 5′-tccaaagacagcagaaaactttcg-3′;
mouse Cyclophilin Rev: 5′-tcttcttgctggtcttgccattcc-3′.
Figure 3. Expression of S1P-metabolizing enzymes is defective in the striatum of YAC128 HD mice. 
Representative cropped immunoblottings and densitometric analysis of SGPL1 and SPHK1/2 isoform 
expression in striatal (A–C) and cortical (D,E) tissues from manifest (9 month old) YAC128 mice and WT 
littermates. Value are represented as mean ± SD. N = 5 for each group of mice. *p < 0.05; **p < 0.001 (Unpaired 
t-test).
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Analysis of apoptosis. Apoptosis was assessed as previously described34. In THI experiments, cells were 
cultured in standard growth medium for three days in the presence and absence of THI, then they were placed 
at 39 °C for five hours in SFM. In K145, EMD567731, SK1-I and DMS experiments, cells were pre-treated with 
each inhibitor at 33 °C for 1 hour in serum-free medium (SFM) and then placed at 39 °C for five hours. In K6PC-5 
experiments, cells were incubated in SFM and placed at 39 °C for five hours in the presence and absence of the 
SPHK1 activator. At the end of each treatment, cells were collected and incubated with FITC-conjugated Annexin 
V (BD, Cat. N. 556419), according to the manufacturer’s instructions. Fluorescence-activated cell sorting (FACS) 
analysis was performed as previously described34.
Statistics. Two side Paired and Unpaired t-tests were used as indicated. Data are expressed as mean ± SD.
Results
Expression of sphingolipid-metabolizing enzymes is aberrant in HD human post-mortem 
brains. Deregulated expression and activity of sphingolipid-metabolizing enzymes have been recently 
described in animal models and patients with a range of chronic neurodegenerative conditions25, 26, 28, 51. Here, 
in order to investigate whether similar biochemical defects also occur in HD, we analyzed post-mortem striatal 
and cortical specimens from patients with advanced HD (grade III-IV)40 compared to gender and age-matched 
healthy controls (Table 1). Immunoblotting analysis showed that the expression of SGPL1 was robustly increased 
in both the striatum and cortex of these HD patients (Fig. 2A and E) and this was further confirmed by immuno-
histochemistry (Fig. 2B and F). In line with the hypothesis that there is a major disturbance in the regulation of 
either the synthesis or degradation of sphingolipids, increased SGPL1 was associated with a significant reduction 
of SPHK1 in the striatum of the same HD patients when compared to healthy controls (Fig. 2C). Although a trend 
towards a similar reduction of SPHK1 protein expression in the cortex was seen, this did not reach statistical 
significance (Fig. 2G). No changes in the expression profile of multiple isoforms52–54 of SPHK2 could be detected 
neither in the striatum nor in the cortex (Fig. 2D and H).
S1P-metabolizing enzymes in HD animal models showed an expression profile similar to that 
seen in the HD human post-mortem samples. In order to clarify whether alterations in the sphingo-
lipid metabolic pathways are relevant to the neurodegenerative process in HD, we examined brain tissues from 
two different HD mouse models (YAC128 and R6/2 mice).
Figure 4. Expression of S1P metabolizing enzymes is defective in brain tissues from R6/2 HD mice. 
Representative cropped immunoblottings and densitometric analysis of SGPL1 and SPHK1/2 isoform 
expression in striatal (A–C) and cortical (D,E) tissues from manifest (11 week old) R6/2 mice and WT 
littermates. Values are represented as mean ± SD. N = 6–9 for each group of mice. **p < 0.001 (Unpaired t-test).
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Biochemical analysis of all three SGPL1, SPHK1 and SPHK2 proteins, in the striatal tissues from manifest 
YAC128 mice, showed expression profiles similar to that in human tissues (Fig. 3A–C). While expression of 
SGPL1 was significantly increased (Fig. 3A), levels of multiple isoforms52, 53, 55 of SPHK1 were markedly reduced 
in these HD mice when compared to wild-type (WT) littermates (Fig. 3B). No changes in the expression of 
SPHK2 isoforms were, indeed, observed (Fig. 3C). When cortical tissues were analyzed, no variation was 
observed in any of the three proteins (Fig. 3D–F).
To further investigate the aberrant sphingolipid metabolism in HD, biochemical analyses were extended 
to brain tissues from manifest R6/2 mice (Fig. 4) which express exon 1 of human HTT with over 150 poly-Q. 
Importantly, protein expression profiles of either SGPL1 or SPHK1 in these mice mirrored the pattern seen in 
YAC128 mice and human samples in both striatum and cortex (Fig. 4A,B). Indeed, SPHK2 expression showed a 
slight, but not significant trend toward the increase in the striatum (Fig. 4C) and was considerably incremented 
in the cortex (Fig. 4F).
Brain tissues of manifest R6/2 mice showed perturbed bioavailability of essential sphingolip-
ids. Expression levels of either SGPL1 or SPHKs have been previously associated with an altered bioavailability 
of the bioactive sphingolipid, S1P56, 57. In order to verify whether a similar association exists in HD, sphingolipid 
Figure 5. Levels of essential sphingolipids are defective in brain tissues from R6/2 mice. Lipidomic analysis 
by LC-MS/MS of S1P, Sph and Cer content in striatal (A–C) and cortical (D,F) tissues from manifest (11 week 
old) R6/2 mice and WT littermates. Values are represented as mean ± SD. N = 7–10 for each group of mice. 
*p < 0.05; **p < 0.001; ***p < 0.0001 (Unpaired t-test). Representative immunohistochemical micrograph (G) 
and dot blotting and densitometric analysis (H) of Cer content in the cortex of manifest R6/2 mice and WT 
littermates. Scale bar in each micrograph represents 100 µm. Data are represented as mean ± SD. N = 5 for each 
group of mice. **p < 0.001 (Unpaired t-test).
Figure 6. Levels of Glucosylceramides (GluCer) are reduced in brain tissues from R6/2 mice. Lipidomic 
analysis by LC-MS/MS of GluCer content in the striatal (A) and cortical (B) tissues from manifest (11 week 
old) R6/2 mice and WT littermates. Values are represented as mean ± SD. N = 7 for each group of mice. 
**p < 0.001(Unpaired t-test).
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content in R6/2 mouse brains was determined by a targeted sphingolipidomic analysis44. Consistent with the 
immunoblotting analyses, mass spectrometry revealed a significant reduction of S1P content in both striatum and 
cortex of manifest R6/2 mice (Fig. 5A and D).
Beside the defective expression of the metabolizing enzymes, SPGL1 and SPHKs (Fig. 4), reduced levels of S1P 
in the brain tissues of R6/2 mice may be attributable to altered levels of Sph or to an overall imbalanced sphingo-
lipids rheostat. Accordingly, quantitative analysis by Mass Spectrometry highlighted a significant increase of Sph 
in the striatum of R6/2 mice (Fig. 5B), however no changes were observed in the cortex (Fig. 5E). Mass spectral 
data revealed also a complex Cer profile in these two specific brain regions. Although the striatal tissues displayed 
increased levels of only one Cer species (C24:0), cortical tissues showed accumulation of different molecular 
species of the same lipid (C20:0, C22:0, C24:0 and C24:1) (Fig. 5C–F). Accumulation of Cer in the cortex was con-
firmed by immunohistochemical and dot blotting analysis (Fig. 5G–H). This accumulation was also associated 
with a reduction of some GluCer species as shown in Fig. 6.
Sphingolipid metabolism is aberrant at early stage of the disease in brain tissues from R6/2 
mice. In order to assess whether alteration of sphingolipid metabolism may represent an early biological event, 
potentially underlying HD pathophysiology, we investigated the expression of S1P-metabolizing enzymes in both 
striatal and cortical tissues from early manifest (6 week old) R6/2 mice. Importantly, immunoblotting analysis 
showed a significant increase of SGPL1 levels in both regions already at such early stage of the disease. No differ-
ence in SPHK1 and 2 expression was indeed detectable (Fig. 7A–F). Interestingly, semi-quantitative analysis by 
dot blotting pointed out also a robust increase of Cer content in the cortex of the same mice (Fig. 8A). This result 
was confirmed by immuhistochemical analysis (Fig. 8B).
Pharmacological modulation of S1P-metabolizing enzyme activity regulates pro-survival path-
ways in HD cells. Modulation of sphingolipid metabolizing-enzyme activity has been widely described to 
alter the bioavailability of S1P and by so doing cellular homeostasis and survival58, 59.
In order to investigate the potential role of all three S1P-metabolizing enzymes in HD cellular homeostasis, we 
undertook pharmacological studies (Fig. 9D) in mice striatal-derived knock in cell lines expressing endogenous 
Figure 7. Levels of both SGPL1 are defective in brain tissues from R6/2 mice at early stages of the disease. 
Representative cropped immunoblottings and densitometric analysis of SGPL1 and SPHK1/2 isoform 
expression in striatal (A–C) and cortical (D,E) tissues from early manifest (6 week old) R6/2 mice and WT 
littermates. Values are represented as mean ± SD. N = 5 for each group of mice. **p < 0.001 (Unpaired t-test).
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levels of wild type (STHdh7/7) or mHtt (STHdh111/111) and where levels of S1P have been previously reported to 
be reduced32.
In line with our earlier data, both protein and gene expression of these enzymes was markedly abnormal 
in these cells (Fig. 9A,B,E,F and I–L). While higher levels of SGPL1 in the mHtt cells were associated with an 
increased susceptibility to apoptosis (Fig. 9A–C), its pharmacological inhibition by 2-acetyl-4-(tetrahydroxy-
butyl) imidazole (5 μM THI) re-established the vulnerability of these cells to cell death to the extent that they 
behaved as WT cells (Fig. 9C). Increased expression of SGPL1 was paralleled by visibly higher levels of SPHK2 
(Fig. 9E,F), and according to other studies31, its inhibition by either K145 (1.5 μM) or EMD567731 (5 and 10 μM) 
significantly protected cells form apoptosis (Fig. 9G,H).
Contrary to what was found for SGPL1 and SPHK2, levels of SPHK1 were significantly reduced in HD cells 
(Fig. 9I–L). Although the impact that such an imbalance may have on cell function is not clear yet, pharmaco-
logical inhibition of SPHK1 by either SK1-I (5 μM) or DMS (15 μM) further exacerbated the susceptibility of HD 
cells to apoptosis (Fig. 9M,N).
Finally, with the aim of elucidating the extent to which SPHK1 may influence cell survival in the presence of 
mHtt, we evaluated the potential beneficial effect of its pharmacological activation by using K6PC-5, a selective 
stimulator of SPHK1 activity60–62. Importantly, treatment with 50 μM K6PC-5 significantly mitigated the vulnera-
bility of cells to apoptosis (Fig. 9O) and rapidly induced the activation of either AKT or ERK in both WT and HD 
cells as shown in Fig. 9P,Q. Importantly, administration of K6PC-5 triggered a slight, but significant increase of 
both phospho-AKT and phospho-ERK also in iPSC-derived cortical neurons from HD patients (Fig. 10A,B and 
Supplementary Fig. 2).
Discussion
There is increasing evidence that links perturbed sphingolipid metabolism to a range of different neurodegener-
ative conditions including HD4, 25, 26, 28.
In this study, we consolidated the evidence that sphingolipid metabolism is aberrant in HD and represents 
a common pathogenic denominator among multiple preclinical models of the disease and in human patients. 
Also, we demonstrated for the first time, that expression of S1P-metabolizing enzymes is significantly altered. 
In particular, we have found that such a defect shows some regional variation in the HD brain, with especially 
consistent expression profile abnormalities seen between SPGL1 and SPHK1 in the striatal tissues of all our HD 
human samples and animal models. Up-regulation of SGPL1 was consistently paralleled by down-regulation of 
Figure 8. Levels of ceramides are increased in cortical tissue from R6/2 mice at early stages of the disease. 
Representative dot blotting and densitometric analysis (A) and immunohistochemical micrograph. Scale bar in 
each micrograph represents 100 µm. (B) of Cer content in the cortex of early manifest (6 week old) R6/2 mice 
and WT littermates. Data are represented as mean ± SD. N = 5 for each group of mice. *p < 0.05 (Unpaired 
t-test).
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Figure 9. Pharmacological modulation of S1P metabolizing enzyme activity regulates cell survival in HD 
striatal derived cells. Cropped immunoblotting of SGPL1 protein (A) and mRNA expression levels (B) from 
STHdh7/7 and STHdh111/111 cells. Values are mean ± SD of three experiments performed in triplicate. *p < 0.05 
(Unpaired t-test). Analysis of apoptosis in STHdh cell lines first cultured for three days in complete medium 
in the absence and presence of 5 μM THI and then incubated for five hours in serum free medium to induce 
apoptosis (C). Values are mean ± SD of two experiments performed in quadruplicate. **p < 0.001(Unpaired 
t-test). Schematic representation of the pharmacological interventions to modulate the activity of S1P-
metabolizing enzymes (D). Cropped immunoblotting of SPHK2 protein (E) and mRNA expression levels (F) 
from STHdh7/7 and STHdh111/111 cells. Values are mean ± SD of three experiments performed in triplicate. 
*p < 0.05 (Unpaired t-test). Analysis of apoptosis in STHdh cell lines incubated for five hours in serum free 
media in the presence or absence of either 1.5 μM K145 (G) or 5 and 10 μM EMD567731 (H) SPHK2 inhibitors. 
Values are mean ± SD of three experiments, each performed in triplicate. *p < 0.05; **p < 0.001 (Unpaired 
t-test). Cropped immunoblotting of SPHK1 protein (I) and mRNA expression levels (L) from STHdh7/7 and 
STHdh111/111 cells. Values are mean ± SD of three experiments performed in triplicate. *p < 0.05 (Unpaired 
t-test). Analysis of apoptosis in STHdh cell lines incubated for five hours in serum free media in the presence 
or absence of 5 μM SK1-I (2R, 3S, 4E)-N-methyl-5-(4′-pentylphenyl)-2-aminopent-4-ene-1,3-diol) (M) and 
15 μM DMS (N,N-Dimethylsphingosine) (N). Data are mean ± SD of three experiments, each performed in 
triplicate. **p < 0.001 (Unpaired t-test). Apoptosis in STHdh cell lines incubated for five hours in serum-free 
medium in the presence or absence of 50 μM K6PC-5 (O). Data are mean ± SD of three experiments, each 
performed in triplicate. **p < 0.001; ****p < 0.0001 (Unpaired t-test). Cropped immunoblotting of AKT and 
ERK phosphorylation in cellular protein extracts from STHdh7/7 (P) and STHdh111/111 (Q) cell lines measured at 
different time points after K6PC-5 treatment.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 5280  | DOI:10.1038/s41598-017-05709-y
SPHK1, which, under physiological conditions, is known to act as a pro-survival kinase in both CNS and periph-
eral tissues18, 63, 64.
The role of SPHK2 in HD, indeed, remains elusive. The significance of the differential expression of SPHK2 
between brain tissues from R6/2 mice and YAC128 mice and HD patients is not straightforward, however it may 
be that SPHK2 has different roles depending on when and where it is expressed or on its subcellular localization65. 
Very recent findings reported a detrimental effect of SPHK2 in different in vitro models of the disease65. Thus, we 
speculate that elevation of its expression in brain tissues from R6/2 mice may be toxic and further contribute to 
the worsening of the disease in this mouse model.
Alteration in the expression of S1P-metabolizing enzymes may theoretically correlate with a defective avail-
ability of the bioactive lipids in HD. Accordingly, lipidomic analysis revealed a significant decrease in the levels 
of S1P in both striatum and cortex of manifest R6/2 mice. Our study also provides the first in vivo evidence of 
perturbed ceramide homeostasis, whose increased levels have been described to interfere with mitochondrial 
channel formation, exert pro-apoptotic actions66, 67 and to be associated with different neurodegenerative condi-
tions39, 68, 69.
Where the reduction of S1P content in the brain tissues of R6/2 mice comes from, is currently unclear. 
However, taking into account the abnormal increase of Sph levels in the striatum along with accumulation of 
different Cer species in the cortex of these mice and, considering also the increased levels of S1P-degradative 
enzyme, SGPL1, in both brain regions, disturbed S1P homeostasis may be due to a combination of poor conver-
sion of Cer to S1P, through Sph production and/or to its enhanced degradation.
Importantly, abnormal expression of SGPL1 and higher levels of Cer, already detectable at early stage of dis-
ease in R6/2 mice, likely suggest that S1P metabolism is precociously affected in HD.
This finding corroborated our previous evidence demonstrating that perturbations of the sphingolipid metab-
olism occur early in the disease9. Moreover, the absence of defects in the expression of both SPHK1 and 2 proteins 
in early manifest mice also indicates that such alterations may progress with the worsening of the disease.
Although not investigated how huntington mutation may alter the expression of S1P-metabolizing enzymes, 
its early occurrence may likely be attributable to gene expression deregulations, as they may take place before 
disease onset70. To this regard, evidence indicates that SGPL1 gene expression is usually negatively regulated by 
the micro RNA - miRNA 125b71. Interestingly, expression of miRNA 125b is described being down-regulated 
in different pre-clinical models of HD including R6/2 mice72. In the light of that, we hypothesize that SGPL1 
over-expression may be likely attributable to micro RNA dysregulation. However, our findings suggested that 
aberrant enzyme protein content likely depends on altered gene expression.
From our perspective, our findings provide first insights into perturbed S1P metabolism, which does not rep-
resent an epiphenomenon connected to the worsening of the disease, but rather a mutation-dependent biological 
event with a potential pathogenic role in HD.
Along this line, pharmacological interventions aimed at modulating S1P metabolism may pave the way for 
the development of more targeted and effective therapeutic strategies for the treatment of HD. Our results are 
in line with recent evidence showing the potential beneficial effect of modulation of SPHKs in vitro30, 31, and 
strengthen our previous findings demonstrating a neuroprotective effect of the S1P receptor stimulation in vivo34. 
Figure 10. Pharmacological activation of SPHK1 evokes activation of pro-survival pathways in human iPSC-
derived neurons. Representative cropped immunoblottings and densitometric analysis of AKT (A) and ERK (B) 
phosphorylation in iPSC-derived HD human neurons (day 65) after 30 minute of treatment with K6PC-5. Data 
are mean ± SD of three experiments, * p < 0.05 (Paired t-test).
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Importantly, the beneficial effects of pharmacological modulation of S1P-metabolizing enzymes in HD human 
iPSC-derived neurons, further support our hypothesis.
We believe that the novelty of our study lies in the evidence that alteration in S1P metabolism may represent 
a new hallmark of the disease as it is shared amongst preclinical models of HD and most importantly visible also 
in human post-mortem brains. In addition, its early occurrence corroborates the hypothesis that defective sphin-
golipid homeostasis may likely contribute to the development of HD. In conclusion, in our opinion what makes 
our findings attractive is the evidence that sphingolipid metabolism may represent a target for the discovery of 
novel therapeutic strategies in HD, especially given that drugs working through its related pathways are already 
in clinical trial for different other pathological conditions73, 74.
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